Thus, based on this mechanism of action, the PD-L1/PD-L2 expressed on the surface of tumor cells can be inhibited from binding the PD-1 expressed on the surface of the T lymphocytes, so that they can activate the innate or adaptive immune responses and destroy the tumor cells (Figure 2). This evidence concerns the gene PDCD1 and neoplasm.